Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 447, 131 (10 May 2007) | doi:10.1038/447131a; Published online 9 May 2007
Open Innovation Challenges
-
Methods to Analyze Consumer Emotions
The Seeker is looking for methods to analyze consumer emotions. This Challenge requires only a writ...
-
Methods of Modeling Adaptation in Populations
The analysis of adaptation with a population is a frequently encountered computational modeling scen...
- More Challenges
- Powered by:
nature jobs
Senior Researcher in theoretical chemistry / physics
- Italian Institute of Technology
- Lecce, Italy
PhD Student Position in International PhD Program in Life Science, Munich
- International Max Planck Research School for Molecular and Cellular Life Sciences
- Munich 82152 Germany
Cheap at any price?
Abstract
As AstraZeneca shells out $15 billion for a mid-sized US biotech firm, Heidi Ledford reports on the startling cost of staying in the drugs business.
When MedImmune, a Maryland biotechnology company, announced on 12 April that it was looking for a buyer, market watchers were unsurprised. Shareholders had long been calling for just such a sale as the best remedy for the company's poor stock performance and sluggish revenue growth — and rumours of an impending deal were already doing the rounds.
To read this story in full you will need to login or make a payment (see right).
